JP2010518090A5 - - Google Patents

Download PDF

Info

Publication number
JP2010518090A5
JP2010518090A5 JP2009549129A JP2009549129A JP2010518090A5 JP 2010518090 A5 JP2010518090 A5 JP 2010518090A5 JP 2009549129 A JP2009549129 A JP 2009549129A JP 2009549129 A JP2009549129 A JP 2009549129A JP 2010518090 A5 JP2010518090 A5 JP 2010518090A5
Authority
JP
Japan
Prior art keywords
group
lower alkyl
independently selected
hydrogen
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009549129A
Other languages
English (en)
Other versions
JP2010518090A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/001754 external-priority patent/WO2008130464A1/en
Publication of JP2010518090A publication Critical patent/JP2010518090A/ja
Publication of JP2010518090A5 publication Critical patent/JP2010518090A5/ja
Pending legal-status Critical Current

Links

Claims (1)

  1. 式Iの化合物
    Figure 2010518090
    およびその薬学的に許容される塩であって、
    式中、
    R1は、シクロアルキル基、置換シクロアルキル基、低級アルキル基、および置換低級アルキル基から成る群より選択され、
    R2は、低級アルキル基および置換低級アルキル基から成る群より選択され、
    R3は、アルキル基、ヒドロキシ基またはカルボキシ基で置換されるアルキル基、およびアリール基で置換されるアルキル基から成る群より選択され、
    R4、R5a、R5b、R6、およびR7は、水素および低級アルキル基から成る群より独立して選択され、
    R8aおよびR8bは、水素および低級アルキル基から成る群より独立して選択され、
    Yは、CR9aR9bであって、R9aおよびR9bは、水素および低級アルキル基から成る群より独立して選択され、
    Zは、以下より選択され、
    Figure 2010518090
    式中、(A)および(Y)は、それぞれ、Zの式IのCRaRbおよびYへの結合を示し、
    L1、L2およびL3は、O、およびCR10aR10bから成る群より独立して選択され、R10aおよびR10bは、水素および低級アルキル基から成る群より独立して選択され、
    M1、M2、M3およびM4は、CおよびNから成る群より独立して選択されるが、M1、M2、M3およびM4のうち1つ以下が窒素であるということを条件とし、
    X1、X2、X3、X4、X5、X6およびX7は、水素、ハロゲン、トリフルオロメチル基、ヒドロキシ基、アルコキシ基、および低級アルキル基から成る群より独立して選択され、
    mは、0または1であり、nは、1または2である、
    式Iの化合物、およびその薬学的に許容される塩。
JP2009549129A 2007-02-09 2008-02-08 大環状グレリン受容体修飾因子およびその使用方法 Pending JP2010518090A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88916307P 2007-02-09 2007-02-09
PCT/US2008/001754 WO2008130464A1 (en) 2007-02-09 2008-02-08 Macrocyclic ghrelin receptor modulators and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014056805A Division JP6047514B2 (ja) 2007-02-09 2014-03-19 大環状グレリン受容体修飾因子およびその使用方法

Publications (2)

Publication Number Publication Date
JP2010518090A JP2010518090A (ja) 2010-05-27
JP2010518090A5 true JP2010518090A5 (ja) 2011-03-31

Family

ID=39497450

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009549129A Pending JP2010518090A (ja) 2007-02-09 2008-02-08 大環状グレリン受容体修飾因子およびその使用方法
JP2014056805A Expired - Fee Related JP6047514B2 (ja) 2007-02-09 2014-03-19 大環状グレリン受容体修飾因子およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014056805A Expired - Fee Related JP6047514B2 (ja) 2007-02-09 2014-03-19 大環状グレリン受容体修飾因子およびその使用方法

Country Status (12)

Country Link
US (3) US9371297B2 (ja)
EP (2) EP2644618B1 (ja)
JP (2) JP2010518090A (ja)
KR (1) KR20090107088A (ja)
CN (1) CN101657436A (ja)
AU (1) AU2008241532A1 (ja)
BR (1) BRPI0807046A2 (ja)
CA (1) CA2677399C (ja)
EA (1) EA200901077A1 (ja)
ES (2) ES2602789T3 (ja)
MX (1) MX2009008574A (ja)
WO (1) WO2008130464A1 (ja)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7521420B2 (en) * 2003-06-18 2009-04-21 Tranzyme Pharma, Inc. Macrocyclic antagonists of the motilin receptor
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US20090198050A1 (en) * 2003-06-18 2009-08-06 Tranzyme Pharma Inc. Macrocyclic Modulators of the Ghrelin Receptor
US8921521B2 (en) 2003-06-18 2014-12-30 Ocera Therapeutics, Inc. Macrocyclic modulators of the Ghrelin receptor
US8088733B2 (en) * 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
WO2008100448A2 (en) * 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US20080287371A1 (en) * 2007-05-17 2008-11-20 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex
EP2259791A2 (en) * 2008-03-05 2010-12-15 Tel HaShomer Medical Research Infrastructure and Services Ltd. Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
EP2403518A4 (en) * 2009-03-06 2013-01-23 Angstrom Pharmaceuticals Inc Compositions and methods for modulating cell migration
EP2475361B1 (en) * 2009-09-09 2019-11-06 Novaremed Ltd. N-substituted benzenepropanamides for use in the treatment of pain and inflammation
WO2011041584A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
CA2778503A1 (en) * 2009-10-23 2011-04-28 Tranzyme Pharma, Inc. Macrocyclic inhibitors of serine protease enzymes
AU2010313282A1 (en) 2009-10-30 2012-05-24 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
AU2011223563A1 (en) * 2010-03-05 2012-11-01 Angstrom Pharmaceuticals, Inc. Modulation of intracellular signaling
EP2566502A4 (en) * 2010-05-04 2013-10-09 Glaxosmithkline Llc METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
CN103347517B (zh) 2010-08-11 2018-10-02 德雷克塞尔大学 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
CN102557989B (zh) * 2011-12-19 2013-12-25 深圳翰宇药业股份有限公司 优利莫瑞林中间体以及优利莫瑞林制备方法
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
WO2013175805A1 (en) * 2012-05-25 2013-11-28 Raqualia Pharma Inc. Ghrelin receptor agonists for the treatment of achlorhydria
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP6467513B2 (ja) * 2015-01-28 2019-02-13 アラタナ セラピューティクス、 インコーポレイテッド 体重増加用化合物の長期使用のための組成物と方法
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
TW202045001A (zh) 2019-02-01 2020-12-16 美商富曼西公司 作為除草劑的經取代吡啶類及嘧啶類化合物
SG11202108026UA (en) * 2019-02-08 2021-08-30 Socpra Sciences Sante Et Humaines S E C Neurotensinergic agonists and methods of using same preventing or treating pain
CN109879935B (zh) * 2019-03-04 2020-11-20 南京工业大学 一种多肽的液相合成方法
CN113616654B (zh) * 2021-06-18 2022-08-12 广州市妇女儿童医疗中心 Gsk872在制备治疗肠道病毒71型感染导致的疾病的药物中的用途
CN115960080B (zh) * 2021-10-13 2024-03-15 南京知和医药科技有限公司 一种多环化合物及其作为胃饥饿素受体激动剂的用途

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
SE7510153L (sv) * 1974-09-12 1976-05-07 American Cyanamid Co Alkanolaminer
NZ188418A (en) 1977-10-03 1981-02-11 Mobil Oil Corp Lubricants containing oil and an oxazoline
JPS56142272A (en) * 1980-04-09 1981-11-06 Teikoku Hormone Mfg Co Ltd Hydrazinopyridazine derivative
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
DE68922602T2 (de) 1988-01-28 1995-12-07 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
JPH03502326A (ja) 1988-01-28 1991-05-30 ポリゲン ホールディング コーポレイション 成長ホルモン放出活性を有するポリペプチド化合物類
US5158978A (en) * 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise
WO1992007578A1 (en) 1990-10-25 1992-05-14 Genentech, Inc. Use of protective agents against reactive oxygen species
US6294346B1 (en) * 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
WO1994011012A1 (en) 1992-11-06 1994-05-26 Merck & Co., Inc. Substituted dipeptide analogs promote release of growth hormone
US5726319A (en) 1992-11-06 1998-03-10 Merck & Co., Inc. Biphenyl substituted dipeptide analogs promote release of growth hormone
CZ151495A3 (en) 1992-12-11 1995-12-13 Merck & Co Inc Spiropiperidine derivatives, process of their preparation and a pharmaceutical composition containing thereof
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
BR9407869A (pt) 1993-10-19 1996-10-29 Merck & Co Inc Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose
AU1172995A (en) 1993-11-09 1995-05-29 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5494919A (en) 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
AU684878B2 (en) 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
US5721251A (en) 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
UA42747C2 (uk) 1993-12-23 2001-11-15 Ново Нордіск А/С Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
HU221092B1 (en) 1993-12-23 2002-08-28 Novo Nordisk As Compounds with growth hormone releasing properties
WO1995034311A1 (en) 1994-06-13 1995-12-21 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
US5783582A (en) 1994-07-20 1998-07-21 Merck & Co., Inc. Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
WO1996022996A1 (fr) 1995-01-25 1996-08-01 Nippon Chemiphar Co., Ltd. Derives de dihydrophenazine
MX9705710A (es) 1995-01-27 1997-10-31 Novo Nordisk As Compuestos con propiedades de liberacion de la hormona del crecimiento.
AU4534596A (en) 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1996024587A1 (en) 1995-02-09 1996-08-15 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5559128A (en) 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
WO1996033189A1 (en) 1995-04-19 1996-10-24 Merck & Co., Inc. Process for the preparation of spiroindolines
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
EP0828754B1 (en) 1995-05-29 2005-02-02 Pfizer Inc. Dipeptides which promote release of growth hormone
HUP9802821A3 (en) 1995-06-22 2000-03-28 Novo Nordisk As Compounds with growth hormone releasing properties
AU6772996A (en) 1995-08-21 1997-03-12 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
ZA966891B (en) 1995-08-21 1998-02-16 Lilly Co Eli 2-acylaminopropanamines as growth hormone secretagogues.
EP0766966A3 (en) 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
AU7169696A (en) 1995-09-26 1997-04-17 Merck & Co., Inc. 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
US5767124A (en) 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
WO1997015191A1 (en) 1995-10-27 1997-05-01 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
CA2235511A1 (en) 1995-10-27 1997-05-01 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
EA199800337A1 (ru) 1995-10-27 1998-10-29 Мерк Энд Ко., Инк. Способ получения гормона роста, усиливающего секрецию
ATE279440T1 (de) 1995-12-13 2004-10-15 Merck & Co Inc Wachstumshormonsekretionsförderer rezeptorfamilie
ATE334394T1 (de) 1995-12-13 2006-08-15 Merck & Co Inc Testverfahren für die sekretionsrezeptoren von wachstumshormonen
IT1277113B1 (it) 1995-12-20 1997-11-04 Romano Deghenghi Composti oligopeptidici contenenti d-2-alchiltriptofano in grado di promuovere la liberazione dell'ormone della crescita
WO1997022367A1 (en) 1995-12-20 1997-06-26 Merck & Co., Inc. Radiolabeled growth hormone secretagogue
ES2323159T3 (es) 1995-12-22 2009-07-07 Novo Nordisk A/S Compuestos con propiedades de liberacion de la hormona del crecimiento.
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU2334097A (en) 1996-03-21 1997-10-10 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
WO1997036873A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
SE9601397D0 (sv) 1996-04-12 1996-04-12 Pharmacia Ab Use of growth hormone
JP2000510453A (ja) 1996-04-19 2000-08-15 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン遊離特性を有する化合物
CN1127488C (zh) 1996-04-24 2003-11-12 诺沃挪第克公司 具有生长激素释放特性的化合物
US5919777A (en) 1996-04-24 1999-07-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
EP0900086A4 (en) 1996-05-07 2000-01-12 Merck & Co Inc IMPROVING THE SLEEP BY MEANS OF A SUBSTANCE PROMOTING THE SECRETION OF GROWTH HORMONES
WO1997041878A1 (en) 1996-05-07 1997-11-13 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
AU2764797A (en) 1996-05-14 1997-12-05 Novo Nordisk A/S Somatostatin agonists and antagonists
WO1997044042A1 (en) 1996-05-22 1997-11-27 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
KR20000016204A (ko) 1996-05-31 2000-03-25 한센 핀 베네드, 안네 제헤르 골다공증의 주기적(연계) 치료에 있어 성장호르몬 성분 및 뼈의항흡수 약물
AU3434697A (en) 1996-07-22 1998-02-10 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1998010653A1 (en) 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
WO1998018815A1 (en) 1996-10-25 1998-05-07 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
SE9703929D0 (sv) 1996-11-22 1997-10-28 Pharmacia & Upjohn Ab Therapeutical use and method
AU6747498A (en) 1997-04-11 1998-11-11 Sumitomo Pharmaceuticals Company, Limited Benzene derivatives
GB2324726A (en) 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
GB9709082D0 (en) * 1997-05-06 1997-06-25 Ciba Geigy Ag Organic compositions
JP2000514838A (ja) 1997-05-14 2000-11-07 藤沢薬品工業株式会社 成長ホルモンの放出を促進するピペリジノ誘導体
AU7906998A (en) 1997-06-20 1999-01-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
JP3514774B2 (ja) 1997-06-25 2004-03-31 ファイザー・インク 成長ホルモン分泌促進薬としてのジペプチド誘導体
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
ZA987383B (en) 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
DE69836386T2 (de) 1997-08-22 2007-10-11 Kaken Pharmaceutical Co., Ltd. Amide zur Förderung der Ausschüttung von Wachstumshormonen
EP1012189B1 (en) 1997-09-08 2007-10-31 Metabolic Pharmaceuticals Ltd. Treatment of obesity
EP1506969B1 (en) 1998-01-16 2010-06-09 Helsinn Therapeutics (U.S.), Inc. Compounds with growth hormone releasing properties
WO1999039730A1 (fr) 1998-02-09 1999-08-12 Kaken Pharmaceutical Co., Ltd. Preparation a administration orale contenant des peptides favorisant la secretion d'hormone de croissance
CN1291994A (zh) 1998-03-03 2001-04-18 诺沃挪第克公司 新的(2e)-5-氨基-5-甲基已-2-烯酸n-甲基-n-((1r)-1-(n-甲基-n-(1r)-1-(甲基氨基甲酰基)-2-苯2基氨基甲酰基-2-(2-萘基)2基酰胺的盐
US6657063B1 (en) 1998-04-30 2003-12-02 Pfizer Inc. Combinations of β3 agonists and growth hormone secretagogues
PL194560B1 (pl) 1998-05-11 2007-06-29 Novo Nordisk As Związki o właściwościach uwalniania hormonu wzrostu, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
JP4574849B2 (ja) 1998-06-09 2010-11-04 サファイア セラピューティクス,インコーポレイティド 成長ホルモン放出特性を有する化合物を調製するための方法
PA8475901A1 (es) 1998-06-16 2000-05-24 Pfizer Prod Inc Terapia de combinacion para la fragilidad musculoesqueletica
CN1305378A (zh) 1998-06-16 2001-07-25 辉瑞产品公司 治疗肌与骨骼的脆性的(选择性)雌激素受体调节剂(serm)和生长激素促分泌素(ghs)的药物组合物
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO2000001726A1 (en) 1998-06-30 2000-01-13 Novo Nordisk A/S Compounds with growth hormone releasing properties
EP1112282A4 (en) 1998-08-10 2002-10-31 Merck & Co Inc RECEPTOR OF THE GROWTH HORMONE SECRETION PROMOTER FROM THE DOG
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
AU5301199A (en) 1998-08-20 2000-03-14 Sumitomo Pharmaceuticals Company, Limited Oxindole derivatives as growth hormone releasers
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
EP1158996A4 (en) 1999-02-18 2005-01-12 Kaken Pharma Co Ltd NEW AMID DERIVATIVES AS GROWTH HORMONE SECRETION CONVEYORS
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
AU5911000A (en) 1999-06-30 2001-01-31 Zymogenetics Inc. Sgip peptides
CA2284459C (en) 1999-10-04 2012-12-11 Neokimia Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
US20040092511A1 (en) 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
TWI263496B (en) 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
US6849597B2 (en) 1999-12-28 2005-02-01 Kaken Pharmaceutical Co., Ltd. Neuroprotective drug
EP1149583A3 (en) 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
DOP2001000154A (es) 2000-05-25 2002-05-15 Pfizer Prod Inc Combinación de secretagogos de hormona del crecimiento y antidepresivos
US6967237B2 (en) 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
ATE302181T1 (de) 2000-06-13 2005-09-15 Zentaris Gmbh Verbindungen zur stimulation der sekretion von wachstumshormonen
WO2001097831A1 (fr) 2000-06-23 2001-12-27 Kaken Pharmaceutical Co., Ltd. Agents therapeutiques et prophylactiques destines a l'insuffisance cardiaque
US6576686B1 (en) 2000-06-27 2003-06-10 Exxonmobil Chemical Patents Inc. Road marking compound comprising linear tetrablock copolymers
KR20020010206A (ko) * 2000-07-27 2002-02-04 이시우 인터루킨 12와 보조활성인자 b7.1 유전자를 함유하는dna 벡터 및 이벡터가 도입된 항암 세포백신
US20020168343A1 (en) 2001-02-14 2002-11-14 Curiel David T. Combined transductional and transcriptional targeting system for improved gene delivery
WO2002078683A1 (en) * 2001-03-29 2002-10-10 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
ITMI20011445A1 (it) 2001-07-06 2003-01-06 Europ Geie Analoghi della cortistantina capaci di legarsi selettivamente ai recettori dei secretagoghi dell'ormone della crescita
AU2003225073A1 (en) * 2002-04-18 2003-11-03 The University Of Iowa Research Foundation Methods of inhibiting and treating bacterial biofilms by metal chelators
JPWO2004014412A1 (ja) 2002-08-09 2005-12-02 科研製薬株式会社 心筋細胞保護剤
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
WO2004084943A1 (en) 2003-03-19 2004-10-07 Beth Israel Deaconess Medical Center, Inc Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
GB0307863D0 (en) 2003-04-04 2003-05-14 Merck Sharp & Dohme Therapeutic treatment
MXPA05012463A (es) 2003-05-27 2006-01-30 Altana Pharma Ag Combinaciones farmaceuticas de un inhibidor de bomba protonica y un compuesto que modifica la motilidad gastrointestinal.
GB0313772D0 (en) 2003-06-13 2003-07-23 Merck Sharp & Dohme Therapeutic treatment
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7521420B2 (en) 2003-06-18 2009-04-21 Tranzyme Pharma, Inc. Macrocyclic antagonists of the motilin receptor
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
NL1024009C2 (nl) 2003-07-28 2005-02-07 Vmi Epe Holland Loopvlakapplicatieinrichting.
US7550431B2 (en) * 2003-07-31 2009-06-23 Tranzyme Pharma Inc. Spatially-defined macrocycles incorporating peptide bond surrogates
ES2357235T7 (es) 2003-07-31 2013-02-14 Tranzyme Pharma Inc. Compuestos macrocíclicos definidos espacialmente útiles para el descubrimiento de fármacos
WO2005039625A1 (en) 2003-10-28 2005-05-06 Rheoscience A/S Growth hormone secretagogue receptor agonists
US7504506B2 (en) 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
EP1729743A1 (en) 2004-01-06 2006-12-13 Panacea Biotec Limited Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
TW200530181A (en) 2004-01-13 2005-09-16 Bristol Myers Squibb Co Heterocyclic compounds useful as growth hormone secretagogues
WO2005097174A2 (en) 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
JP2007532495A (ja) 2004-04-07 2007-11-15 ガストロテック・ファルマ・アクティーゼルスカブ グレリン欠乏を治療するための分泌促進薬の使用
US7034050B2 (en) 2004-04-28 2006-04-25 Romano Deghenghi Pseudopeptides growth hormone secretagogues
US20050277677A1 (en) 2004-06-10 2005-12-15 Heiman Mark L Method for treating emesis with ghrelin agonists
WO2006005613A1 (en) 2004-07-14 2006-01-19 Novartis Ag Combination of dpp-iv inhibitors and compounds modulating 5-ht3 and/or 5-ht4 receptors
BRPI0513713A (pt) 2004-07-28 2008-05-13 Glaxo Group Ltd derivados de piperazina úteis para o tratamento de distúrbios gastrointestinais
WO2006020930A2 (en) 2004-08-12 2006-02-23 Sapphire Therapeutics, Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
AU2005277389A1 (en) 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
US8143425B2 (en) 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
WO2006046977A1 (en) * 2004-10-26 2006-05-04 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and methods of using the same
WO2006045314A2 (en) 2004-10-27 2006-05-04 Gastrotech Pharma A/S Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
EP1812044A2 (en) 2004-10-27 2007-08-01 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
DK1814590T4 (da) * 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Behandling af obesitet og beslægtede sygdomme.
CU23529A1 (es) 2005-03-02 2010-06-17 Ct Ingenieria Genetica Biotech Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune
CA2583345A1 (en) * 2005-06-13 2006-12-28 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
EP1906951A4 (en) 2005-07-01 2009-05-27 Dynogen Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING HYPOMOTILITY OF THE DIGESTIVE SYSTEM AND RELATED DISORDERS
PT1937262T (pt) 2005-09-29 2019-08-21 Ipsen Pharma Sas Composição para utilização no tratamento de dismotilidade gastrointestinal
US8088733B2 (en) * 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders

Similar Documents

Publication Publication Date Title
JP2010518090A5 (ja)
JP2011518833A5 (ja)
JP2013537203A5 (ja)
JP2010530897A5 (ja)
JP2010095546A5 (ja)
JP2016514159A5 (ja)
MY161903A (en) Substituted piperidines as ccr3 antagonists
JP2010519270A5 (ja)
JP2011500769A5 (ja)
JP2013542218A5 (ja)
NO330968B1 (no) Ny fremgangsmate for syntesen av (1S)-4,5-dimetoksy-1-(metylaminometyl)-benzocyklobutan og addisjonssalter derav, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
JP2014526554A5 (ja)
JP2009263394A5 (ja)
JP2012502111A5 (ja)
JP2014500861A5 (ja)
JP2012526168A5 (ja)
JP2010504286A5 (ja)
JP2013063968A5 (ja)
JP2009538861A5 (ja)
JP2010520214A5 (ja)
JP2011529502A5 (ja)
MY149400A (en) Bridged six-membered ring compounds
JP2007517826A5 (ja)
JP2012507535A5 (ja)
JP2013544854A5 (ja)